RNA editing in suicide, major depression and animal model of depression

描述（由申请人提供）：据估计，全球每年约有100万人死于自杀。作为死亡的主要原因之一，自杀在世界范围内受到越来越多的关注，许多国家（包括美国）制定了国家预防战略。高达90%的自杀者至少患有一种精神疾病（例如，重度抑郁症（MDD）、双相情感障碍（BPD）、精神分裂症（SZ））。自杀的生物学基础是否与共病精神疾病的生物学基础不同尚不清楚。在我们的“初步研究”中，我们检查了患有BPD或SZ并因自杀或其他原因死亡的人以及没有自杀的精神正常对照者前额叶皮层（PFC）中5-HT2CR的mRNA编辑。我们发现编辑的增加与自杀有关，但与精神病学诊断、人口统计学特征、精神活性药物、酒精或药物滥用无关。基于这些发现，我们假设mRNA编辑过程的改变可能是导致个体倾向于自杀行为的因素之一。该应用程序将进一步研究这一现象，以确定其在不同临床人群和不同大脑区域中的特异性，并阐明未来药物干预自杀行为的分子靶点。我们最初的研究集中在BPD和SZ患者身上。然而，考虑到大多数自杀发生在重度抑郁症患者中，如果不研究5-HT2CR编辑在重度抑郁症背景下的作用，就不能坚定地确定这一现象对自杀行为的特异性。此外，我们的初步研究是在控制决策和冲动的PFC进行的。然而，毫无疑问，自杀有一个情感因素，我们将在拟议的应用中通过评估杏仁核和前扣带皮层的编辑来解决这个问题。这两个区域是皮质边缘回路的关键部分，参与情绪调节，在抑郁症中受损。为了从患者在疾病过程中服用的药物诱导的自杀中梳理出预期的5-HT2CR编辑变化，我们将使用暴露于不可预测的慢性轻度应激（UCMS）的小鼠进行平行研究，这是研究动物抑郁方面的既定模型。特别是，我们将研究在接受和不接受抗抑郁药物治疗的ucms暴露小鼠中的编辑改变。编辑改变（如果观察到）将与在重度抑郁症和/或自杀患者中检测到的变化进行比较。我们也将迈出第一步，阐明与自杀相关的基因编辑变异的分子机制。尽管5-HT2CR编辑受到许多不同因素的影响，但最明显的解释是编辑酶（作用于RNA或ADARs的腺苷脱氨酶）活性的改变。因此，我们将尝试评估adar在自杀和/或重度抑郁症中的活性。

DESCRIPTION (provided by applicant): The estimated global burden of suicide is about one million deaths per year. Being one of the leading causes of death, suicide receives increasing attention worldwide, with many countries (including USA) developing national strategies for prevention. Up to 90% of adults who commit suicide have at least one psychiatric diagnosis (e.g., major depressive disorder (MDD), bipolar disorder (BPD), schizophrenia (SZ)). Whether the biological underpinnings of suicide are distinct from those of the comorbid psychiatric disorders is unclear. In our "initial study" we examined mRNA editing of 5-HT2CR in the prefrontal cortex (PFC) of persons who had suffered from BPD or SZ and died by suicide or other causes as well as in psychiatrically normal controls without suicides. We detected an increase in editing that was associated with suicide but not with the psychiatric diagnoses, demographic characteristics, psychoactive medications, alcohol or drug abuse. Based on these findings, we hypothesize that an alteration in the mRNA editing process may be one of the factors that predispose individuals toward suicidal behavior. The proposed application will investigate this phenomenon further to establish its specificity among different clinical populations and different brain regions as well as to elucidate molecular targets for future pharmacological interventions against suicidal behavior. Our initial study was focused on persons with BPD and SZ. However, given that the majority of suicides occur in persons with MDD, confidence in specificity of this phenomenon for suicidal behavior cannot be firmly established without studying 5-HT2CR editing in the context of MDD. In addition, our initial study was performed in the PFC that control decision-making and impulsivity. However, there is undoubtedly an affective component to suicide, which we will address in the proposed application by assessing editing in the amygdala and the anterior cingulate cortex. These two regions are the crucial elements of the corticolimbic circuitries that are involved in mood regulation and that are compromised in depression. In an attempt to tease out the anticipated 5-HT2CR editing changes in suicide from those that are induced by medications taken by the patients in the course of the disease, we will perform a parallel study using mice exposed to the unpredictable chronic mild stress (UCMS), which is an established model to study aspects of depression in animals. In particular, we will investigate editing alterations in UCMS-exposed mice with and without antidepressant treatment. The editing alterations (if observed) will be compared to those detected in humans with MDD and/or suicide. We will also take a first step toward elucidating the molecular mechanisms underlying the suicide- associated variations in editing. Although 5-HT2CR editing is influenced by many different factors, the most obvious explanation is an alteration in the activity of the editing enzymes (adenosine deaminases that act on RNA or ADARs). Thus, we will attempt to assess the activity of ADARs in suicide and/or MDD. PUBLIC HEALTH RELEVANCE: Despite dramatic improvements in the pharmacological treatment of psychiatric disorders associated with suicide, there has been relatively little change in suicide rates over the past 25 years. Effective pharmacological approaches toward suicidal behavior can be developed only if biological mechanisms specific for suicide are understood. According to our initial study, one of those suicide-specific mechanisms may initiate from an alteration in the mRNA editing process. The proposed application will investigate this phenomenon further, aiming to elucidate molecular targets for future pharmacological interventions against suicidal behavior.